Most Immunotherapy Fails to Meet ASCO Value Framework – Medscape
|
Most Immunotherapy Fails to Meet ASCO Value Framework
Medscape Most Immunotherapy Fails to Meet ASCO Value Framework. Roxanne Nelson, RN, BSN. January 08, 2018. New immunotherapies, such as the checkpoint inhibitors, have created a great deal of excitement in the oncology community because of their potential to … |
